Stock Ratings / Health Care / PGEN / dividends

HCM (46) RCUS (35) PHVS (63) SUPN (56) ⌘ Pro Terminal →

Precigen Inc. (PGEN) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.64 +9.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Precigen Inc. (PGEN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.38B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PGEN)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PGEN)

✓Walkthrough of PGEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +59.62%📐 HORIZONTAL RANGE

2026-10-30O $6.49H $7.04L $6.49C $6.64VOL 7.93M

RES: $9.93SUP: $5.91SMA50: $7.22SMA200: $5.27

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PGEN Butterfly Map → + Track PGEN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +146.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PGEN)

Health Care Rank #808 of 1016 ⚔️ HCM vs PGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PGEN vs. HCM, RCUS, PHVS, SUPN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Precigen Inc. (PGEN) ranks #808 by composite RQD confidence (35/100, grade D-) and #226 by equity capitalization ($2.38B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HCM leads on capital efficiency and profitability with -2.5% ROIC and — gross margin. PHVS currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PGEN at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PGEN ACTIVE Precigen Inc.	D-	35/100	—	—	-35.0%	+9.21%	$2.38B	Benchmark Subject
HCM HUTCHMED (China) Limited	D	46/100	5.2x	—	-2.5%	+2.03%	$2.37B	/hcm-vs-pgen →
RCUS Arcus Biosciences Inc.	D-	35/100	—	—	-35.0%	+1.20%	$2.37B	/rcus-vs-pgen →
PHVS Pharvaris N.V.	C	63/100	—	—	—	+2.32%	$2.34B	/phvs-vs-pgen →
SUPN Supernus Pharmaceuticals Inc.	D+	56/100	—	89.6%	-4.5%	+1.85%	$2.43B	/supn-vs-pgen →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001356090

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precigen Inc. (PGEN) reported GAAP revenue of $9.7M (+146.7% vs. FY2024 revenue of $3.9M , and +55.6% cumulative change since FY2023) , GAAP net income of -$250.6M, operating cash flow of -$87.8M, and free cash flow of -$89.8M (-17.0% YoY). On the balance sheet, PGEN closed FY2025 with $155.5M in total assets against $93.2M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.7M	-$250.6M	-$87.8M	-$89.8M	$155.5M	$93.2M
FY2024 (FY)	2024-12-31	$3.9M	-$126.2M	-$68.2M	-$76.8M	$145.3M	$0
FY2023 (FY)	2023-12-31	$6.2M	-$95.9M	-$66.9M	-$66.9M	—	—

3. PGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Precigen Inc. (NASDAQ: PGEN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $6.64 (+9.21% 1D, market cap $2.38B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PGEN ranks #808 in composite RQD confidence.

How does PGEN compare to HCM and RCUS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PGEN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HCM (HUTCHMED (China) Limited) holds a D grade (46/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.37B) and RCUS (Arcus Biosciences Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.37B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HCM leads on capital efficiency (-2.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PGEN?

Per PGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001356090), Precigen Inc. generated $9.7M in revenue (+146.7% YoY), -$250.6M in net income, and -$89.8M in free cash flow against $155.5M in total assets and $93.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

PGEN last traded at $6.64 (+9.21% on volume of 7,742,821 shares), positioning the stock -8.03% below its 50-day simple moving average ($7.22) and +26.00% above its 200-day simple moving average ($5.27). Across its 52-week range of $3.04 to $8.98, PGEN sits at the 60.6% percentile with a 14-day RSI of 50.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.81 to $7.47).

PGEN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does PGEN pay a dividend and is it safe?

Precigen Inc. (PGEN) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: PGEN RQD Cockpit PGEN 12M Forecast PGEN Earnings & Move PGEN Dividends & DRIP PGEN Insiders & 13F PGEN Whale Options PGEN Profit Sankey PGEN News & Why